Safety profile and pharmacokinetics of a synthetic cannabinoid (JWH-018)
Completed
- Conditions
- JWH-018, synthetic cannabinoid, safety, pharmacokinetics
- Registration Number
- NL-OMON29562
- Lead Sponsor
- Maastricht University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 55
Inclusion Criteria
•Used cannabis between 2 times a month and 2 times a week during the previous year
•Age between 18 and 40 years
Exclusion Criteria
•History of drug abuse (other than the use of cannabis) or addiction (determined by the medical questionnaire, drug questionnaire and medical examination)
•Experience with synthetic cannabis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method vital signs (body temperature, blood pressure, heart rate and respiratory rate), clinical laboratory safety (haematology, clinical chemistry and urinalysis) and side effects
- Secondary Outcome Measures
Name Time Method Pharmacokinetics and pharmacodynamics
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of JWH-018 in synthetic cannabinoid receptor modulation?
How does JWH-018 compare to standard cannabis-based therapies in safety and efficacy profiles?
Are there specific biomarkers associated with JWH-018 pharmacokinetic variability in clinical populations?
What adverse events have been reported in synthetic cannabinoid trials and how are they managed?
What is the therapeutic potential of JWH-018 in combination with other GPR55 modulators for cannabinoid-related disorders?